Multivesicular Liposome NSAID Formulation for Joint Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NSAID therapies for pain and inflammation are limited by gastrointestinal toxicity and require high systemic doses to achieve efficacious levels at the synovial site, leading to side effects and increased costs.
Innovation Solution
Development of multivesicular liposome formulations encapsulating NSAIDs, which provide sustained release and direct delivery to the joint synovial cavity, reducing systemic exposure and side effects while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high systemic doses of NSAIDs are administered to achieve efficacious levels at the synovial site, then therapeutic efficacy is improved, but gastrointestinal toxicity and side effects increase
Solution Approach 1:
The patent uses multivesicular liposomes as an intermediary delivery system to transport NSAIDs directly to the synovial cavity. The liposomal formulation acts as a mediator that bypasses the gastrointestinal tract and systemic circulation, delivering the drug directly to the target site while minimizing exposure to healthy tissues
Solution Approach 2:
The invention implements local quality by concentrating the NSAID delivery specifically at the synovial cavity rather than distributing it systemically. The multivesicular liposomes are designed to release drugs locally at the injection site, creating high local concentrations where needed while maintaining low systemic levels
2Quantity of substance
If high systemic doses of NSAIDs are administered, then drug levels at the synovial site are improved, but systemic exposure and side effects increase
Solution Approach 1:
The patent segments the drug delivery process into distinct compartments using multivesicular liposomes with multiple internal vesicles. This segmentation allows the drug to be contained and released in a controlled manner at the target site, preventing premature systemic distribution and reducing overall systemic exposure while maintaining adequate local concentrations
3Ease of operation
If oral NSAID therapy is used, then ease of administration is improved, but gastrointestinal complications increase
Solution Approach 1:
The multivesicular liposome formulation serves as an intermediary that changes the route of administration from oral to intraarticular injection. This intermediary delivery system eliminates direct contact with the gastrointestinal tract, thereby preventing gastrointestinal complications while still providing effective drug delivery to the synovial cavity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multivesicular liposome formulations achieve prolonged drug release, reducing gastrointestinal toxicity and side effects, allowing for lower doses and more effective pain relief with fewer systemic toxicities, thereby enhancing the economic viability of NSAID therapy.
Implementation Method 1
The in vitro release profiles demonstrated that both formulations released >80% of the encapsulated drug within 72 h, with the chitosan-TPGS MVLs showing a more sustained release pattern compared to the commercial suspension
Implementation Method 2
The in vitro release profiles demonstrated that both formulations released >80% of the encapsulated drug within 72 h, with the chitosan-TPGS MVLs showing a more sustained release pattern
Implementation Method 3
remote loading a non-steroidal anti-inflammatory drug into said multivesicular liposomes, wherein a gradient of low pH outside the MVL to high pH inside the MVL is present to drive the NSAID into the MVL
Data Source
AI summary
Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.